Collectively, these findings underscore the significant role of UBE2T in LUAD progression, suggesting that its identification as a core player in NSCLC provides a foundation for future research and the development of targeted therapies to improve the prognosis of NSCLC patients. Here, UBE2T is linked to non-small cell lung carcinoma.